Article
Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer--a pilot study.
Folia histochemica et cytobiologica - 24 Apr 2012
Krawczyk Paweł, Wojas-Krawczyk Kamila, Mlak Radosław, Kucharczyk Tomasz, Biernacka Beata, Milanowski Janusz
Abstract excerpt
Platinum-based chemotherapy is the main type of I-line treatment of advanced and non-operative NSCLC patients without EGFR gene mutation. The excision repair cross-complementation group 1 (ERCC1) is an enzyme that executes the incision of the damaged DNA strand and removes platinum-induced DNA adducts. We investigated whether ERCC1 gene polymorphism has an effect on the response to chemotherapy and survival in 43...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.